Saccharomyces boulardii
Trials 20 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02637167 Comparator | Mar 2016 → Jun 2019 | systolic heart failure | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01143272 Comparator | Jun 2010 → Oct 2012 | Clostridium difficile colitis, diarrheal disease | Bernhard Nocht Institute for Tropical Medicine | Terminated | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT03539913 Comparator | Jun 2017 → Jun 2018 | gastroenteritis | Biocodex | Completed | No outcome recorded |
| Phase 4 | NCT03692299 Comparator | Jun 2015 → Jul 2019 | small intestinal bacterial overgrowth, systemic sclerosis | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00807326 Comparator | Nov 2008 → Aug 2009 | diarrheal disease | McNeil AB | Completed | No outcome recorded |
| Phase 4 | NCT00543478 Comparator | Oct 2007 → Jul 2008 | irritable bowel syndrome | Aga Khan University | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | saccharomyces boulardii | “Saccharomyces Boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective...” PMID 34869495 ↗ Nov 202127“Probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) per oral, three times a day, for 8 weeks” NCT05993247 ↗ “To evaluate the efficacy of locally delivered saccharomyces boulardii on clinical and microbiological parameters in the treatment of chronic periodontitis.” NCT03516370 ↗ “A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes” NCT04919850 ↗ “Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin” NCT03220542 ↗ “Drug: Saccharomyces boulardii” NCT03997279 ↗ |
| Known as | CNCM I-745 | “Our aim was to compare the efficacy and safety of 2 probiotics (Saccharomyces boulardii CNCM I-745 vs a 4-strain mixture of Bacillus clausii O/C, SIN, N/R, T) for the treatment of PAGE.” PMID 36086703 ↗ Sep 2022 |
| Known as | Florastor | “Saccharomyces Boulardii 250 MG [Florastor]” NCT06149676 ↗ |
| Known as | S. boulardii | “CONCLUSIONS: Metronidazole treatment is partially effective in SIBO, but S. boulardii in monotherapy or in combination improves the gastrointestinal outcomes in SSc.” PMID 31549334 ↗ Sep 20191“or S. boulardii (250 mg twice daily for 5 days)” PMID 26541878 ↗ Dec 2015 |
| Known as | Sac. boulardii | “The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD.” NCT01143272 ↗ |
| Known as | Saccharomyces boulardii CNCM I-745 | “Saccharomyces boulardii CNCM I-745 is a probiotic yeast that has proven efficacy for the treatment of acute gastroenteritis and antibiotic-associated diarrhea.” NCT04627337 ↗ |
| Known as | Saccharomyces cerevisiae var. boulardii | “The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD.” NCT01143272 ↗ |
| Known as | Sacchraomyces Boulardii | “Effect Of A Locally Delivered Probiotic Sacchraomyces Boulardii In The Management Of Chronic Periodontitis” NCT03516370 ↗ |
| Modality | Other / unclassified | “Saccharomyces Boulardii is a probiotic yeast” NCT00543478 ↗ |
| Route | Oral | “Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days” NCT00807326 ↗ |